Incoming HOPA President Amy Seung on What to Expect at the 2026 Annual Conference — and Why Oncology Pharmacists Have Never Mattered More

For oncology pharmacists, the Hematology/Oncology Pharmacy Association Annual Conference is more than a meeting—it’s a recalibration. It's where clinicians who have spent months keeping pace with a relentless wave of approvals, expanded indications, and emerging toxicity data finally get to pause, compare notes, and figure out what it all means for their patients. Few people understand that dynamic better than Amy Seung, PharmD, BCOP, FHOPA, CHCP, vice president of oncology pharmacy strategy at MJH Life Sciences and incoming HOPA president. For Seung, HOPA isn't just professionally valuable—it’s essential.

The pace of change in oncology pharmacy, she notes, is no longer annual or even monthly. New data, new trials, and new clinical questions are arriving on a weekly, sometimes daily, basis, and the gap between what gets published and what gets implemented in practice remains one of the field's most pressing challenges. That gap, she argues, is precisely what HOPA is built to close.

This year's conference promises a particularly rich program, with pharmacist-led research, best-practice presentations on bispecific therapies, real-world evidence on solid tumor and hematologic malignancies, and deep dives into supportive care and toxicity management all on the agenda. For those who can't make it to New Orleans in person, Seung points to virtual CE options, live social media coverage, and Pharmacy Times' real-time conference reporting as ways to stay connected. And for everyone in the field, she has one more date to mark on the calendar: April 3 — the inaugural Oncology Pharmacist Day.